Related Experiment Video
Updated: Aug 7, 2026
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Hematopoietic stem cell transplant research with pediatric donors: when can institutional review boards approve it?
Jehanna M Peerzada1, David Wendler
1National Institutes of Health, Department of Clinical Bioethics, Bethesda, MD 20892, USA.
Insights
Children can donate hematopoietic stem cells (HSCs) for research if the procedure poses minimal risk. Institutional Review Boards (IRBs) evaluate research-specific risks, with exceptions for higher-risk protocols requiring special approval.
Area of Science:
- Pediatric Hematology
- Transplant Research Ethics
- Institutional Review Boards
Background:
- Pediatric donation of hematopoietic stem cells (HSCs) for allogeneic transplants is established clinically.
- Ethical considerations for children donating HSCs in research settings are less defined.
- Existing regulations provide limited guidance on pediatric participation in stem cell research donation.
Purpose of the Study:
- To clarify the ethical and regulatory framework for pediatric hematopoietic stem cell (HSC) donation in research.
- To determine the conditions under which Institutional Review Boards (IRBs) can approve children's participation as HSC donors in research.
- To outline the risk assessment criteria for pediatric HSC donors in research protocols.
Main Methods:
- Analysis of existing ethical guidelines and regulatory frameworks concerning pediatric research participation.
- Review of Institutional Review Board (IRB) approval criteria for research involving human subjects, specifically minors.
- Examination of risk-benefit assessments pertinent to pediatric hematopoietic stem cell (HSC) donation procedures in research.
Main Results:
- Institutional Review Boards (IRBs) may approve pediatric participation as HSC donors in research if risks are no more than minimal.
- Risk assessment must differentiate between research-specific risks and those inherent to the donation procedure itself.
- Protocols involving greater than minimal risk for pediatric HSC donors require special approval from the Secretary of Health and Human Services.
Conclusions:
- Children can ethically participate as hematopoietic stem cell (HSC) donors in research under specific minimal-risk conditions.
- IRBs play a crucial role in evaluating research-specific risks for pediatric HSC donors.
- A pathway exists for approving higher-risk pediatric HSC donation research through specific federal authorization.
Abstract:
Although pediatric donation of hematopoietic stem cells (HSCs) for allogeneic transplants is common in the clinical setting, the question of when children may donate HSCs in research has received little attention. Our analysis reveals that institutional review boards (IRBs) may approve children's participation as HSC donors in transplant research when it poses no more than minimal risk to them. The risks that IRBs should consider are those that result specifically from the research, as opposed to risks donors would have faced regardless of the research. Transplant protocols that expose pediatric donors to more than minimal risk can be approved by the Secretary of U.S. Department of Health and Human Services in a special category of pediatric research.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:01Regulation of Hematopoietic Stem Cells